Clinical trials: Refractory Malignant Neoplasm
Esophageal Cancer
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.
- Trial name
- NCT02569242
- Testing
- Nivolumab, Docetaxel/Paclitaxel
- Where
- 89 sites in United States, Denmark and 6 more
- Volunteers
- 419 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced Malignant Neoplasm, Acute Myeloid Leukemia
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies.
- Conditions
- Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia
- Trial name
- NCT04067336
- Testing
- Ziftomenib, Midazolam, Itraconazole
- Where
- 43 sites in United States, Belgium and 5 more
- Volunteers
- 263 people
- Sponsor
- Kura Oncology, Inc.
Pancreatic Neoplasms
Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies
This study is a Phase I/II study. In Phase I of this study, the objective is to determine the maximum tolerated dose (MTD) of combination therapy with Aroplatin and gemcitabine (Gemzar®) in subjects with unresectable, locally…
- Trial name
- NCT00081549
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Volunteers
- 111 people
- Sponsor
- Aronex Pharmaceuticals
Pancreatic Cancer
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether nitrocamptothecin is more effective than other chemotherapy for cancer of the…
- Trial name
- NCT00005870
- Testing
- fluorouracil, gemcitabine hydrochloride, mitomycin C
- Where
- 2 sites in United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Diffuse Large B Cell Lymphoma，DLBCL
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Purinostat mesylate for injection (PM) was the novel and highly potent Class Ia and IIb HDAC selective inhibitor. The results of regular blood sampling analysis of the mouse B-cell lymphoma model induced by ighmyc transgenic mice…
- Trial name
- NCT05563844
- Testing
- PM 8.4 mg/m^2, PM 11.2 mg/m^2
- Where
- 2 sites in China
- Volunteers
- 74 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Gastric Cancer, Adenocarcinoma
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
- Trial name
- NCT00917384
- Testing
- ramucirumab, Best Supportive Care (BSC)
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Advanced Solid Tumor
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
- Trial name
- NCT06586957
- Testing
- NKT3964, Paclitaxel, Doxorubicin
- Where
- 20 sites in United States, South Korea
- Volunteers
- 238 people
- Sponsor
- NiKang Therapeutics, Inc.
B Cell Lymphoma, NHL, Adult
SynKIR-310 for Relapsed/Refractory B-NHL
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
- Conditions
- B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Trial name
- NCT06544265
- Testing
- SynKIR-310
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Verismo Therapeutics
Solid Tumor, Adult, Advanced Solid Tumor
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer
- Trial name
- NCT04859777
- Testing
- MPT-0118, MPT-0118 + pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Monopteros Therapeutics Inc.
Small Cell Lung Cancer, Advanced Solid Malignant Tumor
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be…
- Trial name
- SCLC (NCT05271292)
- Testing
- Chiauranib
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Solid Tumors, Metastatic Tumors
Phase 1 Study of OTS167 in Patients With Solid Tumors
The purpose of this study is to test the safety and tolerability of an investigational drug called OTS167. OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in…
- Trial name
- NCT01910545
- Testing
- OTS167IV
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- OncoTherapy Science, Inc.
Lymphoma, Malignant
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of bimiralisib (PQR309) administered orally, as once daily capsules…
- Trial name
- NCT02249429
- Testing
- bimiralisib
- Where
- 12 sites in United States, Bosnia and Herzegovina and 4 more
- Volunteers
- 53 people
- Sponsor
- PIQUR Therapeutics AG
Multiple Myeloma and Plasma Cell Neoplasm
Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as fluphenazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00335647
- Testing
- fluphenazine hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Immune Control